Smart Investor
Kapitalmarktausblick 2021
Anzeige

Diskussion zu Immutep WKN: A2H8YL ISIN: US45257L1089 Kürzel: IMMP Forum: Community

2,55 EUR

+0,79 % +0,02

Stand: 28.01.2021 - 08:21:32 Uhr

Zum Wert

Immutep Hoch/Tief

Eröffnung 2,53
Hoch 2,58
Tief 2,48
Vortag 2,53

Community-Beiträge (93)

Neu laden

Schorsch11
Schorsch11 vom 14.01.20 08:10 Uhr

http://stocktwits.com/tripleface/message/190167735

N
NOFX_PC vom 12.01.20 18:37 Uhr

Jupp q1 2020 ist interessant hier 😀

P
Paint vom 12.01.20 13:11 Uhr

Oha jetzt sind wir schon zu dritt. :) es geht Berg auf

N
NOFX_PC vom 12.01.20 12:26 Uhr

https://themarketherald.com.au/immutep-asximm-expands-part-c-of-tacti-002-study-due-to-positive-data-2020-01/

N
NOFX_PC vom 12.01.20 12:25 Uhr

https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-imm/immutep-shares/news/immutep-limiteds-asximm-shift-from-loss-to-profit/

Schorsch11
Schorsch11 vom 09.01.20 07:24 Uhr

http://stocktwits.com/jeremy80/message/189609071

Schorsch11
Schorsch11 vom 06.01.20 20:41 Uhr

Near-Term Upside In LAG-3 Immunotherapy - Buy Immutep Summary LAG-3 - An emerging field in immunotherapy drug development. Immutep's 227 patient study in Metastatic Breast Cancer due to report in March 2020. Downside protection with Big Pharma relationships and multiple clinical trials currently underway. Undervalued stock with than US$100 million market capitalisation. Immutep (ASX:IMM, IMMP) is an Australian primarily listed biotechnology company working primarily in the field of cancer immunotherapy using the Lymphocyte Activation Gene 3 (LAG-3) immune control mechanism. Frederic Triebel, the Founder and Chief Scientist at Immutep, discovered in the late 1990s that a soluble protein called LAG-3 could activate dendritic cells in the vicinity of tumour https://seekingalpha.com/article/4313526?source=ansh $IMMP

Schorsch11
Schorsch11 vom 06.01.20 20:36 Uhr

Prof. Dr. Salah-Eddin Al-Batran, lead investigator of INSIGHT-004 commented: "We are really pleased that INSIGHT-004 recruitment is advancing and that we can start to enroll the second cohort of 6 patients. The treatment's safety profile is consistent with previous trials of efti which is encouraging and it's also good to see early activity signals with one patient reporting a partial response already."  INSIGHT-004 is the fourth arm of the INSIGHT trial which is being conducted by Institute of Clinical Cancer Research, Krankenhaus Nordwest GmbH in Frankfurt, Germany (IKF). It is being conducted under Immutep's collaboration with Merck KGaA, Darmstadt, Germany and Pfizer Inc and is evaluating the safety, tolerability and recommended Phase II dose of Immutep's lead immunotherapy product candidate efti when given in combination with avelumab in 12 patients with advanced solid malignancies. https://www.benzinga.com/pressreleases/19/12/g15016886/insight-004-clinical-trial-update

Schorsch11
Schorsch11 vom 06.01.20 20:33 Uhr

MARKET CAP 62,435,506 SHARES 34,117,763 AV. DAILY VOLUME 34,744 https://www.immutep.com/files/content/investor/investor-update/2017/2002185.pdf 112 gelistete Patente https://patentscope.wipo.int/search/en/result.jsf?_vid=P12-K52UDX-42431 9 klinische Studien https://clinicaltrials.gov/ct2/results?cond=&term=immutep&cntry=&state=&city=&dist=

Schorsch11
Schorsch11 vom 06.01.20 20:28 Uhr

Initial safety data from Phase I INSIGHT-004 Expected in Q4 CY2019 More mature data from TACTI-002 Expected in Q1 CY2020 First data from Phase IIb AIPAC Expected in Q1 CY2020 Final safety data from Phase I TACTI-mel Expected in H1 CY2020

Schorsch11
Schorsch11 vom 06.01.20 20:25 Uhr

WL Financing Update We were very pleased to have the ongoing support of our shareholders as we raised AU$4m in an equity placement and AU$6m from a fully underwritten Entitlement Offer in July 2019. Importantly, the funds raised are expected to extend the Company’s cash runway to the end of calendar year 2020, including a milestone payment of £4m (AU$7.4m) that we received from our partner GSK related to the first patient being dosed in GSK’s Phase II clinical trial evaluating GSK2831781 in ulcerative colitis. Partner milestone payments form an important source of non-dilutive funding for Immutep. The Company is eligible to receive up to £64m (~A$118.17m) in developmental milestone payments from GSK as well as single-digit tiered royalties, if GSK2831781 is commercialised. Overall the Company is in a solid financial position ahead of the coming milestones.

P
Paint vom 05.10.19 18:20 Uhr

Oh ich besitze das Unternehmen alleine :)

P
Paint vom 20.07.19 13:02 Uhr

Ist hier jemand?

P
Paint vom 02.05.19 23:01 Uhr

Nix los hier, sind wir wohl die einzigen beiden Investierten :)

M
Maroni vom 16.06.15 10:10 Uhr

prima aktie

M
Maroni vom 14.06.15 14:04 Uhr

prima

Anzeige
Smartbroker
Der Broker von Deutschlands größter Finanzcommunity
Werbung

Ihre kurzfristige Erwartung an IMMP

IMMP steht am bei
Veränderung:
mgl. Rendite mit
Hebel (Omega)
Zum Produkt